Please assess the completion status of the following clinical trial:

Trial Title: Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a clinical diagnosis of Type II diabetes mellitus, controlled by diet and/or second generation oral hypoglycemic drugs, with the onset of the disease after age 35.~* Are between 0 and 50% above normal body weight (adjusted by frame) according to the Metropolitan Life Insurance Tables.~* Are male or female, aged 36-80 years with a diagnosis made at least 1 year prior to enrollment.~* Have an HbA1c level between 6 and 10%~* Have a fasting serum glucose level between 120-220 mg/dL and not vary by more than ±20% during the month prior to entering the treatment phase and HbA1c levels not vary by more than ±10% during the month prior to entering the treatment phase. Serum glucose level must have been between 120-220mg/dl and the subject's HbA1c between 6 and 10% at Week 0.~* Have been on a stable diet consistent with ADA-recommended dietary guidelines with intake of total dietary fiber \< 15g/1000 calories and were willing to maintain this diet during the 20-week study.~* Have maintained a constant body weight (±5%) during the month prior to entering the treatment phase~Exclusion Criteria:~* Have a condition that would interfere with evaluation

- Gender: ALL
- Minimum Age: 36 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): matched placebo BID
- psyllium 3.4g BID (Type: ACTIVE_COMPARATOR): 3.4g psyllium BID for a Total of 6.8g daily
- 6.8g psyllium BID (Type: ACTIVE_COMPARATOR): 6.8g psyllium BID for a total of 13.6 g/day

Based on this trial design, predict the completion outcome and termination type (if applicable).